The pace of research and development of domestic long-acting diabetes drugs has accelerated, which is good for 500 million patients

"Pharmaceutical network industry dynamics" recently announced that two innovative diabetes drugs "insulin secretion peptide fusion protein injection" and JY09 has entered the clinical trial stage.
also means that the pace of domestic long-acting diabetes drug research and development accelerated, will be good for the domestic 500 million diabetes and prediabetes groups.
diabetes is a combination of genetic and environmental factors that lead to a group of clinical syndromes characterized by chronic hyperglycemia.
years, diabetes is being younger, and the number of diabetics is increasing year by year.
the International Diabetes Federation (IDF), the number of adults with diabetes worldwide reached 463 million in 2019, and that number is expected to increase significantly in the future, reaching 700 million by 2045.
of these, China, as a large country with diabetes, has almost one in ten people with diabetes, and the continued rise in the prevalence of a large population base has led to a rapid increase in the number of people with diabetes.
the number of adults aged 20-79 with diabetes in our country climbed from 0.9 billion to 110 million between 2011 and 2017.
based on the growing number of patients, the domestic diabetes drug market is huge.
anti-diabetic drug market is expected to grow from 51.2 billion yuan in 2017 to 97.8 billion yuan in 2022 and 173.9 billion yuan in 2028, with a compound annual growth rate of 13.8%, according to the data.
in the face of such a huge market, domestic pharmaceutical companies have made efforts to continuously promote innovation results.
this time into the clinical trial stage of the "insulin secretion peptide fusion protein injection", developed by the National Pharmaceutical Group of China's Lanzhou Biological Products Research Institute.
It is understood that insulin-promoting peptide fusion protein injection for the treatment of type 2 diabetes, is gLP-1 perceptogenic drugs, its role is in the body through binding with GLP-1 subjects and activation of the subject, glucose concentration dependence to promote islet β cell secretion of insulin, and reduce islet α cell secretion of glucagolytin, thereby reducing blood sugar, has a safe and effective control of blood sugar.
In the past, diabetics in the use of insulin, sulfonyl sulfonylurea and other conventional drugs, need to be given daily or multiple times a day, and insulin secretion peptide fusion protein injection target administration once a week, can achieve a longer interval of the sugar-lowering effect, more conducive to the treatment of type 2 diabetes patients.
, a new class of biologic drugs developed by Beijing Oriental Baitai Biotech Co., Ltd. to treat type 2 diabetes, has entered the second phase of clinical phase.
This new drug is the use of antibody platform technology, genetic engineering means to develop the treatment of type 2 diabetes, the advantage is to play a tube for half a month, greatly reducing the frequency of the past day three injections, conducive to the need to significantly reduce the patient's pain index, improve the quality of life.
, from a clinical point of view, JY09 can also avoid the risk of hypoglycemia, and can even promote and restore islet cell function, promote insulin secretion, and protect the heart.
, JY09 will have significant advantages in terms of comprehensive efficacy and safety compared to conventional therapeutic drugs.
it is understood that in Beijing high-fine tip industry fund about 150 million yuan of support, the overall research and development of the drug has gone through a decade.
, JY09 is expected to complete clinical studies within three to five years and be eligible for market.
the drug is expected to further break the monopoly of foreign pharmaceutical companies and lower the price of imported drugs.